• LevelJump will issue up to 16,666,667 units at $0.15 per unit for gross proceeds of up to $2,500,000
  • Net proceeds from the financing will be used towards acquisitions and for general working capital purposes
  • The offering is expected to close in late January
  • Leveljump Healthcare is a healthcare company with a focus on profitable telehealth solutions as well as primary care services in radiology
  • Shares in Leveljump Healthcare Corp. (JUMP) are down 4.76 per cent on the day, trading at C$0.10 per share at 12:30 pm EST

LevelJump Healthcare (JUMP) will be conducting a non-brokered private placement financing for gross proceeds of up to $2,500,000.

The company will issue up to 16,666,667 units at $0.15 per unit. Each unit will consist of one common share and one common share purchase warrant. Each warrant will entitle the holder to acquire one additional common share of Leveljump at an exercise price of $0.20 with an expiry date of January 31, 2024.

The net proceeds from the financing will be used towards acquisitions and for general working capital purposes.

The offering is expected to close in late January.

Securities issued will be subject to a four-month hold period in accordance with applicable securities laws.

Leveljump Healthcare is a healthcare company with a focus on profitable telehealth solutions as well as primary care services in radiology. The company provides radiology solutions for hospitals, emergency rooms, and private clinics.

Shares in Leveljump Healthcare Corp. (JUMP) are down 4.76 per cent on the day, trading at C$0.10 per share at 12:30 pm EST.

More From The Market Online
Frequency Exchange's NIKKI wellness device

Boston Bruins president Cam Neely joins Frequency Exchange

Frequency Exchange (TSXV:FREQ), a health technology stock, appoints Boston Bruins president Cam Neely to its advisory board.
image of scientist looking into a microscope

BriaCell begins phase 1/2 trial of Bria-OTS™ for breast cancer

BriaCell Therapeutics (TSX:BCT) initiates a Phase 1/2 clinical trial of Bria-OTS for metastatic breast cancer.